uniQure N.V. Line of Credit Facility, Maximum Borrowing Capacity
uniQure N.V. (QURE) had Line of Credit Facility, Maximum Borrowing Capacity of $50.00 million as of 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Notes › Debt › Line of Credit Facility
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2020-03-02
- 2019-12-31: Line of Credit Facility, Maximum Borrowing Capacity $50.00M.
- 2019-09-30: Line of Credit Facility, Maximum Borrowing Capacity $50.00M.
- 2019-06-30: Line of Credit Facility, Maximum Borrowing Capacity $50.00M.
- 2019-03-31: Line of Credit Facility, Maximum Borrowing Capacity $50.00M.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2019-12-31 | $50.00M 10-K · filed 2020-03-02 |
| 2019-09-30 | $50.00M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $50.00M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $50.00M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $50.00M 10-K · filed 2019-02-28 |
| 2018-12-06 | $30.00M 10-K · filed 2019-02-28 |
| 2018-09-30 | $50.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $50.00M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $50.00M 10-Q · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |